Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
FRISCO, Texas, Jan. 26, 2016 -- Greatbatch Inc., (NYSE:GB) today announced that a jury in the United States District Court for the District of Delaware returned a verdict finding that AVX Corporation and AVX Filters Corporation infringed two Greatbatch patents, and in the process awarded Greatbatch $37.5 million in damages. The complaint, filed in April 2013, alleged that AVX had infringed Greatbatch patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate its patented technology.
The jury's decision marked an important milestone in Greatbatch’s effort to defend its patented technology. “Greatbatch is committed to challenging willful and deliberate patent infringement and to taking all steps necessary to ensure that our intellectual property is protected,” said Thomas J. Hook, Greatbatch president & CEO. "I want to express my sincere appreciation for the time and careful attention the Court and the jury gave this important case."
During trial, Greatbatch presented evidence that certain AVX products infringed claims of U.S. Patent Nos. 5,905,627 and 5,333,095. In advance of trial, the Court determined that the jury should also include damages for infringement of U.S. Patent No. 6,888,715.
In awarding Greatbatch $37.5 million in damages, the jury also confirmed the validity of Greatbatch’s asserted patents, as well as two other Greatbatch patents that AVX had challenged.
Additional information about the case – Greatbatch Ltd. v. AVX Corporation and AVX Filters Corporation, Civil Action No. 13-cv-723-LPS – can be obtained from publicly available court records. Greatbatch was represented in this case by Harris Beach PLLC.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopaedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company’s brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at www.greatbatch.com.
In October 2015, Greatbatch, Inc. completed its acquisition of Lake Region Medical, with the combined company expected to be renamed Integer Holdings Corporation later this year (subject to shareholder approval).
Investor Relations Contact: Anthony Borowicz [email protected] tel 716-759-5809 Media Contact: Christopher Knospe [email protected] tel 716-759-5727
